Aquestive Therapeutics, Inc. (AQST) earnings date
Mar 2, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 42 days, typically, give or take 11 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Tue, Nov 3, 2026 | after close | 34 | 8-K |
| Q2 FY2026 | Tue, Aug 11, 2026 | after close | 42 | 8-K |
| Q1 FY2026 | Wed, May 13, 2026 | after close | 43 | 8-K |
| Q4 FY2025 | Wed, Mar 4, 2026 | after close | 63 | 8-K |
| Q3 FY2025 | Wed, Nov 5, 2025 | after close | 36 | 8-K |
| Q2 FY2025 | Mon, Aug 11, 2025 | after close | 42 | 8-K |
| Q1 FY2025 | Mon, May 12, 2025 | after close | 42 | 8-K |
| Q4 FY2024 | Wed, Mar 5, 2025 | after close | 64 | 8-K |
What they guided beta
| Q3 FY2026 | "Ex-U.S. Anaphylm strategy progressing, with Health Canada submission expected in Q4 2026 and an EU filing planned for Q1 2027" exhibit |
| Q3 FY2026 | "Outside the U.S., the Company expects to submit a New Drug Submission to Health Canada in Q4 2026 and plans to file in the European Union in Q1 2027." exhibit |
| Q3 FY2026 | "The Company expects to conduct additional clinical work beginning in the first quarter of 2027." exhibit |
| Q3 FY2026 | "License and royalty revenue decreased to $0.8 million in the third quarter 2026 from $1.0 million in the third quarter 2025, primarily due to lower estimated royalty revenues." exhibit |
| Q3 FY2026 | "Cash and cash equivalents were $90.3 million as of September 30, 2026. 2026 Outlook Aquestive's full-year 2026 financial guidance remains unchanged." exhibit |
| Q2 FY2026 | "Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026" exhibit |
| Q2 FY2026 | "On track to begin ex-U.S. filings of Anaphylm in Q4 2026" exhibit |
| Q2 FY2026 | "The Company reaffirms its guidance to resubmit the Anaphylm New Drug Application (NDA) in the third quarter of 2026." exhibit |
| Q2 FY2026 | "The Company remains on track to submit regulatory applications in Canada by the end of 2026 and in the European Union in the first quarter of 2027." exhibit |
| Q2 FY2026 | "The Company expects its existing clinical data to support regulatory submissions in additional markets in 2027, including the United Kingdom." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/AQST
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/AQST
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/AQST/"><img src="https://veritasdata.dev/embed/AQST.svg" alt="AQST earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/AQST/)
Script
<script async src="https://veritasdata.dev/embed/AQST.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/AQST"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.